Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

NCT00637832 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped no information

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisolone
DRUG: vincristine sulfate
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

University of Southampton